1. Guidance for industry: patient-reported outcomemeasures: use in medical product development to support labeling claims. 2009 http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.Accessed on August 13, 2020.
2. Opioid Use Disorder: Diagnostic Criteria. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, 2013 .
3. Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to encourage more widespread innovation and development of new treatments for opioid use disorder[press release]. 2018 https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-steps-encourage-more-widespread-innovation-and.Accessed on August 21, 2020.
4. 6C43.2 Opioid dependence IN: ICD-11 forMortality and Morbidity Statistics. 2020a https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f111507461. Accessed on December 21, 2020.
5. OpioidUse Disorder: Endpoints for Demonstrating Effectiveness of Drugs for TreatmentGuidance for Industry. 2020b. https://www.fda.gov/media/114948/download. Accessed on December 17, 2020.